News MorphoSys takeover delivers phase 3 win for Novartis A drug for autoimmune disease Sjögren's syndrome, claimed by Novartis when it bought MorphoSys, could soon be filed for approval.
News GSK and CureVac settle mRNA patent spat with Pfizer/BioNTech BioNTech's takeover of CureVac seems to have unlocked a resolution to some of the patent litigation swirling around mRNA vaccine technologies.
News Click, Boehringer DTx for schizophrenia passes phase 3 test Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app.
News Strand raises $153m for RNA meds, and other bio financings Recent financings in biotech include a $153m Series B for programmable mRNA developer Strand, plus rounds for Artbio, Minghui, and Chai Discovery.
News Lilly weakens on oral weight-loss drug data Shares in Eli Lilly have come under pressure after reporting the results of a phase 3 trial of oral weight-loss candidate orforglipron.
News Pushback against Kennedy's mRNA decision builds The decision by HHS to cut funding for mRNA vaccines has caused dismay among scientists and public health experts, who have labelled it wrong-headed.
News CDC panel votes to scrap hepatitis B birth dose advice CDC advisers vote to overturn decades of US policy and abandon endorsement of universal hepatitis B vaccination for newborns in the US.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
